Drug intelligence / Profile preview

Fluorine-18 P17-059

Development stage: Phase 1
Lead developer: Five Eleven Pharma
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Fluorine-18 P17-059 is a radiopharmaceutical diagnostic agent developed for use as a positron emission tomography (PET) imaging tracer. It is a deuterium-substituted analog of dihydrotetrabenazine labeled with fluorine-18 and designed to bind vesicular monoamine transporter 2 (VMAT2) in the brain. The compound demonstrates high affinity for VMAT2 and enables visualization of dopaminergic neuron integrity via PET/CT imaging. Its primary clinical development has been for the diagnosis of Parkinson's disease and related neurodegenerative disorders affecting the nervous system[1][2][4]. The developer is Five Eleven Pharma[1][5].

Targets

VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on Fluorine-18 P17-059.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fluorine-18 P17-059.

Explore the full profile